Skip to content

Study · Non-randomized trial · 2016

2 results

[Cognitive impairment in patients poluchennym ischemic stroke in the acute and early recovery periods in the process of neuroprotection low-dose drug cortexin].

Belova LA, Mashin VV, Abramova VV, Proshin AN, Ovsjannikova AN

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2016Cited by 3 (Europe PMC)

PMID27905386 (opens in a new tab)DOI10.17116/jnevro20161168240-43 (opens in a new tab)PepBankPUB-27905386
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with ischemic stroke, cortexin (single or repeated course, groups 1 and 2 pooled) produced faster and more complete cognitive disorder regression than basic therapy alone.

    In plain wordsAfter ischemic stroke, cognitive problems regressed faster and more completely with one or two courses of cortexin than with basic therapy alone.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseCognitive disorder regression
    Study

    n: not reported in source

    Comparator
    Basic therapy alone
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    20 mg (10+10) · intramuscularAs given in this study (human).

    Source sentences

    Summary
    It was noted more rapid and complete regression of cognitive disorders in patients of the 1st and 2nd groups, in comparison with patients of the 3rd group.
    2 context sentences
    Summary · context
    The study involved 90 patients with poluchennym ischemic stroke.
    Summary · context
    Patients of the first group received cortexin 20 mg (10+10) intramuscularly on the background of basic therapy, patients of the second group (n=30) received cortexin 20 mg (10+10) two courses for 10 days each with a break in between of 10 days, the patients of the third group - only basic therapy.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with ischemic stroke, the double cortexin course had the best reported effect on cognitive disorders.

    In plain wordsAfter ischemic stroke, the double cortexin course had better effects on cognitive disorders than the single course.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseCognitive disorder regression
    Study

    n: not reported in source

    Comparator
    Other groups (single-course cortexin and basic therapy alone)
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    20 mg (10+10) · intramuscular · Two 10-day courses with a 10-day intervalAs given in this study (human).

    Source sentences

    Summary
    However, the best effect of the therapy was observed still in the group of patients treated with the double rate of the drug cortexin.
    3 context sentences
    Summary · context
    It was noted more rapid and complete regression of cognitive disorders in patients of the 1st and 2nd groups, in comparison with patients of the 3rd group.
    Summary · context
    The study involved 90 patients with poluchennym ischemic stroke.
    Summary · context
    Patients of the first group received cortexin 20 mg (10+10) intramuscularly on the background of basic therapy, patients of the second group (n=30) received cortexin 20 mg (10+10) two courses for 10 days each with a break in between of 10 days, the patients of the third group - only basic therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.